This World Immunization Week, The Big Catch-Up provides an opportunity to reverse the immunization backslide caused by the COVID-19 pandemic and represents a turning point to reach millions of people around the world who are missing out on life-saving vaccines. IVAC’s toolkit provides messaging and resources for immunization advocates to illustrate the importance of restoring and strengthening routine immunization across the globe. #VaccinesWork
Overview

Disruptions to Routine Immunizations during the COVID-19 Pandemic

IVAC researchers led a study analyzing the impact of the COVID-19 pandemic on routine immunization programs in 170 countries. They found that routine administration was affected by disruptions to vaccine demand and supply, as well as reduced availability of the health workforce. Nearly 70% of countries experienced disruptions in their immunization outreach services.

Read the full study published in The Lancet Global Health.

Podcast: The Impact of COVID-19 on Immunizations Around the World

Listen to this podcast episode to hear Dr. Chizoba Wonodi and Dr. Anita Shet discuss the impact of disruptions to immunizations and how maintaining global health systems is critical for avoiding preventable deaths.

"We'll have more deaths from vaccine-preventable diseases like measles if we don't address the issues head on and try to restore services, restore people's confidence in seeking immunization services."
- Dr. Chizoba Wonodi
VIEW-hub
IVAC’s VIEW-hub tracks introduction, access, and coverage data for nine vaccines in 194 countries. Users can download customized visualizations of year-over-year data to visualize how routine immunization has been impacted by the COVID-19 pandemic.

VoICE
Value of Immunization Compendium of Evidence (VoICE) is a searchable database of evidence demonstrating the broad benefits of immunization and the far-reaching impact of vaccine-preventable diseases. This research can be used to demonstrate the importance of restoring and strengthening routine immunization programs across the globe.
Pneumonia and Diarrhea Progress Report

IVAC's annual report tracks progress on 10 indicators related to pneumonia and diarrhea in the 15 countries with the highest burden of under-five pneumonia and diarrhea deaths. The 2022 report highlights the worrying impacts of the COVID-19 pandemic, noting that declines in coverage of key immunizations threaten global progress against preventable child deaths. Read the latest report.

Advocacy Brief – Strengthening Health Resilience in Zero-Dose Communities

In collaboration with Gavi, the Vaccine Alliance, IVAC has developed an advocacy brief on the role of routine immunization in strengthening health resilience. This resource provides recommendations on best practices to help vulnerable communities withstand disease outbreaks and other health crises. Read the brief.
**IA2030 Scorecard**

The **Immunization Agenda 2030 (IA2030) Scorecard** is a publicly available interactive tool displaying data that enables stakeholders at all levels to monitor and track the status of each indicator in the IA2030 Framework for Action. The scorecard supports coordinated operational planning, ownership and accountability, and communication and advocacy. **Learn more.**

---

**Coalition to Strengthen the HPV Immunization Community (CHIC)**

The **Coalition to Strengthen the HPV Immunization Community (CHIC)** brings together the expertise of several partner organizations to build and support optimized local programs, guide rapid country adoption of revisions in schedule recommendations, and accelerate HPV vaccine introduction. Access resources for HPV vaccine advocacy and education **on their website.**

---

**Why are HPV vaccines so critical for cervical cancer control?**
- 99% of cervical cancer cases are linked to the human papillomavirus (HPV). Cervical cancer is one of the most prevalent cancers in the world.
- 85% of the global burden of HPV-related cervical cancer affects women in low- and middle-income countries.

---

**What does the evidence say about HPV vaccine dosing schedules?**
- Studies have looked at 1, 2, and 3-dose schedules.
- Efficacy trials have found that the efficacy of 1, 2, or 3 doses was the same after 10 years.
- Immunogenicity studies have found that a single dose is non-inferior to two or three doses.
VERSE Equity Toolkit

Those living in low-resource settings were disproportionately impacted by the immunization backslide caused by the COVID-19 pandemic. One tool to examine immunization equity is the VERSÉ Equity Toolkit, which assesses the drivers of immunization inequity in a population. This resource can be used to analyze the distribution of immunization coverage and to monitor progress toward equitable access to life-saving vaccines.

VaccineROI.org

Did you know that every $1 invested in vaccine programs provides a return of $21? The Decade of Vaccine Economics (DoVE) project calculated the Return on Investment (ROI) of vaccine programs in 73 low- and middle-income countries. DoVE also estimated the cost of Illness for three vaccine-preventable diseases, which includes preventable childhood illnesses like diarrhea and measles. Explore the brief.